HanAll Biopharma and Harbour BioMed on Tuesday announced agreeing to produce and sell HanAll’s two novel biologics, in Greater China, including Hong Kong, Macau and Taiwan, the anti-FcRn monoclonal antibody, HL161, for the treatment of pathogenic IgG-mediated autoimmune diseases, and the anti-TNF ophthalmic solution, HL036, for dry eye and other inflammatory diseases.
According to the deal, HanAll Biopharma will get up to $81 million in total upfront, development, registration, and sales milestones, as well as royalties on net sales. The rights outside of Greater China are reserved for HanAll. Additional terms were not disclosed.
Seung Kook Park, CEO of HanAll Biopharma, said that teaming with Harbor BioMed’s in the discovery and further production of novel antibody therapeutics within the immunology field and deep expertise in China will enable the acceleration of production of its pipeline products in other countries too, especially in the US and European countries.
Jingsong Wang, , CEO of Harbour BioMed, said: “There are great unmet medical needs that these two innovative compounds can address for Chinese patients. We are looking forward to collaborating with HanAll Biopharma to develop them in Greater China. This collaboration is aligned with our strategy to leverage our global and regional clinical development expertise by in-licensing clinical stage compounds that are complementary to the internal portfolio we are building through our industry leading, transgenic mouse platforms for generating fully human antibodies.”